vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and National Storage Affiliates Trust (NSA). Click either name above to swap in a different company.
National Storage Affiliates Trust is the larger business by last-quarter revenue ($187.0M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 12.2%, a 23.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -1.6%). National Storage Affiliates Trust produced more free cash flow last quarter ($299.8M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -2.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
ADMA vs NSA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $187.0M |
| Net Profit | $49.4M | $22.9M |
| Gross Margin | 63.8% | 72.5% |
| Operating Margin | 45.1% | 20.2% |
| Net Margin | 35.5% | 12.2% |
| Revenue YoY | 18.4% | -1.6% |
| Net Profit YoY | -55.9% | 36.8% |
| EPS (diluted) | $0.20 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $187.0M | ||
| Q3 25 | $134.2M | $188.7M | ||
| Q2 25 | $122.0M | $188.8M | ||
| Q1 25 | $114.8M | $188.4M | ||
| Q4 24 | $117.5M | $190.1M | ||
| Q3 24 | $119.8M | $193.6M | ||
| Q2 24 | $107.2M | $190.4M | ||
| Q1 24 | $81.9M | $196.1M |
| Q4 25 | $49.4M | $22.9M | ||
| Q3 25 | $36.4M | $18.4M | ||
| Q2 25 | $34.2M | $19.5M | ||
| Q1 25 | $26.9M | $13.0M | ||
| Q4 24 | $111.9M | $16.7M | ||
| Q3 24 | $35.9M | $18.7M | ||
| Q2 24 | $32.1M | $17.1M | ||
| Q1 24 | $17.8M | $59.0M |
| Q4 25 | 63.8% | 72.5% | ||
| Q3 25 | 56.3% | 70.7% | ||
| Q2 25 | 55.1% | 70.5% | ||
| Q1 25 | 53.2% | 70.7% | ||
| Q4 24 | 53.9% | 72.5% | ||
| Q3 24 | 49.8% | 72.8% | ||
| Q2 24 | 53.6% | 72.6% | ||
| Q1 24 | 47.8% | 72.1% |
| Q4 25 | 45.1% | 20.2% | ||
| Q3 25 | 38.0% | 15.8% | ||
| Q2 25 | 35.1% | 16.5% | ||
| Q1 25 | 30.4% | 11.0% | ||
| Q4 24 | 32.6% | 14.5% | ||
| Q3 24 | 33.1% | 15.8% | ||
| Q2 24 | 36.6% | 17.2% | ||
| Q1 24 | 26.7% | 48.9% |
| Q4 25 | 35.5% | 12.2% | ||
| Q3 25 | 27.1% | 9.8% | ||
| Q2 25 | 28.1% | 10.3% | ||
| Q1 25 | 23.4% | 6.9% | ||
| Q4 24 | 95.2% | 8.8% | ||
| Q3 24 | 30.0% | 9.7% | ||
| Q2 24 | 29.9% | 9.0% | ||
| Q1 24 | 21.7% | 30.1% |
| Q4 25 | $0.20 | $0.23 | ||
| Q3 25 | $0.15 | $0.17 | ||
| Q2 25 | $0.14 | $0.19 | ||
| Q1 25 | $0.11 | $0.10 | ||
| Q4 24 | $0.45 | $0.19 | ||
| Q3 24 | $0.15 | $0.18 | ||
| Q2 24 | $0.13 | $0.16 | ||
| Q1 24 | $0.08 | $0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $23.3M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $946.0M |
| Total Assets | $624.2M | $5.1B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $23.3M | ||
| Q3 25 | $61.4M | $26.3M | ||
| Q2 25 | $90.3M | $26.1M | ||
| Q1 25 | $71.6M | $19.3M | ||
| Q4 24 | $103.1M | $50.4M | ||
| Q3 24 | $86.7M | $69.9M | ||
| Q2 24 | $88.2M | $59.0M | ||
| Q1 24 | $45.3M | $64.2M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $946.0M | ||
| Q3 25 | $431.2M | $973.1M | ||
| Q2 25 | $398.3M | $1.0B | ||
| Q1 25 | $373.4M | $1.0B | ||
| Q4 24 | $349.0M | $1.1B | ||
| Q3 24 | $231.9M | $986.9M | ||
| Q2 24 | $188.3M | $1.2B | ||
| Q1 24 | $153.7M | $1.3B |
| Q4 25 | $624.2M | $5.1B | ||
| Q3 25 | $568.7M | $5.1B | ||
| Q2 25 | $558.4M | $5.2B | ||
| Q1 25 | $510.6M | $5.3B | ||
| Q4 24 | $488.7M | $5.4B | ||
| Q3 24 | $390.6M | $5.4B | ||
| Q2 24 | $376.4M | $5.3B | ||
| Q1 24 | $350.9M | $5.4B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $338.5M |
| Free Cash FlowOCF − Capex | $34.6M | $299.8M |
| FCF MarginFCF / Revenue | 24.8% | 160.3% |
| Capex IntensityCapex / Revenue | 0.8% | 20.7% |
| Cash ConversionOCF / Net Profit | 0.72× | 14.79× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $541.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $338.5M | ||
| Q3 25 | $13.3M | $100.2M | ||
| Q2 25 | $21.1M | $79.9M | ||
| Q1 25 | $-19.7M | $85.6M | ||
| Q4 24 | $50.2M | $363.1M | ||
| Q3 24 | $25.0M | $105.7M | ||
| Q2 24 | $45.6M | $83.2M | ||
| Q1 24 | $-2.2M | $94.0M |
| Q4 25 | $34.6M | $299.8M | ||
| Q3 25 | $-1.1M | $88.0M | ||
| Q2 25 | $18.7M | $73.8M | ||
| Q1 25 | $-24.4M | $79.9M | ||
| Q4 24 | $47.5M | $344.4M | ||
| Q3 24 | $24.0M | $101.8M | ||
| Q2 24 | $43.6M | $79.5M | ||
| Q1 24 | $-4.6M | $88.6M |
| Q4 25 | 24.8% | 160.3% | ||
| Q3 25 | -0.8% | 46.6% | ||
| Q2 25 | 15.3% | 39.1% | ||
| Q1 25 | -21.2% | 42.4% | ||
| Q4 24 | 40.4% | 181.2% | ||
| Q3 24 | 20.0% | 52.6% | ||
| Q2 24 | 40.7% | 41.7% | ||
| Q1 24 | -5.6% | 45.2% |
| Q4 25 | 0.8% | 20.7% | ||
| Q3 25 | 10.7% | 6.5% | ||
| Q2 25 | 2.0% | 3.2% | ||
| Q1 25 | 4.1% | 3.0% | ||
| Q4 24 | 2.3% | 9.8% | ||
| Q3 24 | 0.9% | 2.0% | ||
| Q2 24 | 1.9% | 1.9% | ||
| Q1 24 | 2.9% | 2.7% |
| Q4 25 | 0.72× | 14.79× | ||
| Q3 25 | 0.36× | 5.44× | ||
| Q2 25 | 0.62× | 4.10× | ||
| Q1 25 | -0.73× | 6.59× | ||
| Q4 24 | 0.45× | 21.70× | ||
| Q3 24 | 0.70× | 5.65× | ||
| Q2 24 | 1.42× | 4.88× | ||
| Q1 24 | -0.12× | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
NSA
Segment breakdown not available.
